<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13a-17 OR 15d-17 THEREUNDER
CORTEX PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
15241 Barranca Parkway, Irvine, California 92718
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (714) 727-3157
----------------------------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1. Title of security Common Stock
------------------------------------------------------------
2. Number of shares outstanding before the change 6,945,598
-------------------------------
3. Number of shares outstanding after the change 7,415,197
--------------------------------
4. Effective date of change April 26, 1996
-----------------------------------------------------
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
conversion of stock
-----------------------------------------------------------------------------
Give brief description of transaction Issuance of Common Stock upon
----------------------------------------
conversion of outstanding shares of Series C Preferred Stock, and 3,306
-----------------------------------------------------------------------------
shares issued upon exercise of stock options.
-----------------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
---------------------------------------------------------
2. Name after change
------------------------------------------------------------
3. Effective date of charter amendment changing name
----------------------------
4. Date of shareholder approval of change, if required
--------------------------
Date May 3, 1996 /s/ D. SCOTT HAGEN
--------------------------------- --------------------------------------
(Officer's signature & title)
D. Scott Hagen
Acting President and Chief Operating
Officer
